Elevance Health Reports Strong Q1 2026 Results, Raises Full-Year Guidance

Key Financial Highlights

• Operating Revenue: \$49.5 billion for Q1 2026, up 1.5% from Q1 2025.
• Diluted EPS: \$8.00; Adjusted Diluted EPS: \$12.58, buoyed by strong operating results and approximately \$1 per share of non-recurring investment income.
• FY 2026 Guidance:
  • Diluted EPS to be at least \$19.85, including estimated financial impact for the CMS matter.
  • Adjusted diluted EPS guidance raised to at least \$26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility.
  • Operating cash flow guidance reaffirmed at at least \$5.5 billion, inclusive of potential cash payments related to the CMS matter.
• Capital Return: \$1.5 billion returned to shareholders in Q1 2026.

Operational and Segment Performance

• Operating Margin: 5.9% in Q1 2026.
• Adjusted Operating Margin: Elevated due to business optimization and integration activities (see reconciliation tables for details).
• Net Investment Income: \$765 million, up 29.7% from Q1 2025, reflecting strong cash management and investment performance.
• Net Income: \$1.76 billion, compared to \$2.18 billion in Q1 2025 (down 19.4%).
• Shareholders’ Net Income: \$1.76 billion, down from \$2.18 billion in Q1 2025.
• Shareholders’ Earnings Per Diluted Share: \$8.00 vs. \$9.61 a year ago (down 16.8%).
• Cash and Cash Equivalents: \$9.66 billion, up from \$7.5 billion at the end of Q1 2025.
• Board Approved Share Repurchase Authorization: Remaining at \$5.6 billion.

Important Shareholder Information & Price-Sensitive Developments

• CMS Matter: The company’s full-year guidance incorporates the estimated financial impact of the CMS notice received in February 2026, which could have implications for future earnings and cash flows. Investors should closely monitor developments on this front as it may affect share value.
• Non-Recurring Investment Income: Q1 2026 results benefited from approximately \$1 per share of non-recurring investment income. This is an important factor for analysts and investors to distinguish between recurring and non-recurring earnings.
• Business Optimization Charges: \$129 million in business optimization program charges, \$47 million in transaction and integration related costs, and \$7 million in litigation and settlement expenses were recorded this quarter. These charges reside in the Corporate & Other segment and impact adjusted results.
• Shareholder Distributions: The company repurchased its common stock for \$1.1 billion at a weighted average price of \$304.68 and paid a quarterly dividend of \$1.72 per share (totaling \$376 million).
• Cash Flow: Operating cash flow for Q1 2026 was robust, with management reaffirming full-year guidance of at least \$5.5 billion, inclusive of potential cash payments for the CMS matter.
• Forward-Looking Statements: The company’s outlook is subject to risks and uncertainties, including regulatory actions, business optimization costs, investment performance, and litigation outcomes. Investors are encouraged to review SEC filings for risk factors.

Segment Details and Health Benefits Revenue

• Health Benefits Segment: Comprises Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid, and Federal Employee Program businesses. Segment performance details can be found in the supplementary schedules.
• CarelonRx and Carelon Services: Performance metrics, including adjusted scripts and revenue, are provided in the reportable segment tables.
• Corporate & Other Segment: Includes charges that affect adjusted net income and operating gain, as detailed in the GAAP reconciliation tables.

Balance Sheet Highlights

• Total Assets: \$125.83 billion as of March 31, 2026, compared to \$121.49 billion a year earlier.
• Total Shareholders’ Equity: \$43.9 billion, essentially flat compared to Q1 2025.
• Noncontrolling Interests: \$140 million.

Cash Flow Details

• Net Cash Provided by Operating Activities: \$4,829 million in Q1 2026, compared to \$4,796 million in Q1 2025.
• Net Cash Used in Investing Activities: \$(1,642) million.
• Net Cash Used in Financing Activities: \$(2,515) million.

GAAP Reconciliation & Non-GAAP Measures

The company references non-GAAP measures such as Adjusted Diluted EPS, Adjusted Operating Expense Ratio, Adjusted Operating Gain, and Adjusted Operating Margin to aid investors in comparing financial results among periods. Reconciliations to GAAP measures are provided in the earnings release and are essential for understanding the underlying business performance.

Risks and Forward-Looking Statements

Elevance Health cautions investors not to place undue reliance on forward-looking statements, which are subject to risks and uncertainties including regulatory changes, market volatility, investment income variability, business optimization costs, and litigation risks. The company advises reviewing its SEC filings to understand these risk factors.

Investor Contacts

• Investor Relations: Nathan Rich ([email protected])
• Media: Leslie Porras ([email protected])

Conclusion – Price Sensitivity

The report contains several price-sensitive items:

• Upward revision of full-year adjusted EPS guidance, reflecting underlying business strength.
• Recognition of non-recurring investment income in Q1, affecting comparability of earnings.
• Impact of the CMS notice and ongoing business optimization/litigation costs.
• Significant capital returned to shareholders, including share repurchases and dividends.

Investors should closely monitor developments regarding the CMS matter, management’s guidance, and nonrecurring items, as these could materially impact share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review official SEC filings and consult with their financial advisors before making investment decisions. The financial data presented is based on unaudited results and management’s estimates as of the reporting date.